The prevalence of metabolic syndrome in people with severe mental illness: A mediation analysis

Social Psychiatry and Psychiatric Epidemiology

Volumn 49, Issue 11, 2014, Pages 1739-1746

  Carrà, Giuseppe ^a   Bartoli, Francesco ^b   Carretta, Daniele ^b   Crocamo, Cristina ^c   Bozzetti, Alberto ^b   Clerici, Massimo ^b   Bebbington, Paul E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Comorbidity; Mental disorders; Metabolic syndrome; Prevalence; Risk factors

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; COMORBIDITY; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; ETHNIC GROUP; FEMALE; HUMAN; ITALY; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SMOKING;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; ITALY; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SMOKING;

EID: 84914698755     PISSN: 09337954     EISSN: 14339285     Source Type: Journal    
DOI: 10.1007/s00127-014-0835-y     Document Type: Article

References (43)

1. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123–1131
2. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population based cohort study (FIN11 study). Lancet 374:620–627
3. Lahti M, Tiihonen J, Wildgust H, Beary M, Hodgson R, Kajantie E et al (2012) Cardiovascular morbidity, mortality and pharma-cotherapy in patients with schizophrenia. Psychol Med 42:2275– 2285
4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364:937–952
5. Galassi A, Reynolds K, He J (2006) Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119:812–819
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497
7. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32
8. Mitchell AJ, Vancampfort D, Sweers K, Van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull 39:306–318
9. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW et al (2009) HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 29:16–20
10. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I et al (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10:52–77
11. Manu P, Correll CU, Van Winkel R, Wampers M, De Hert M (2012) Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry 73:460–466
12. Buhagiar K, Parsonage L, Osborn DP (2011) Physical health behaviours and health locus of control in people with schizophrenia-spectrum disorder and bipolar disorder: a cross-sectional comparative study with people with non-psychotic mental illness. BMC Psychiatry 11:104
13. Kokkinos P, Panagiotakos DB, Polychronopoulos E (2005) Dietary influences on blood pressure: the effect of the Mediterranean diet on the prevalence of hypertension. J Clin Hypertens 7:165–170
14. Salvi V, Albert U, Chiarle A, Soreca I, Bogetto F, Maina G (2008) Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry 30:318–323
15. Bernardo M, Canas F, Banegas JR, Casademont J, Riesgo Y, Varela C, RICAVA Study Group (2009) Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 24:431–441
16. Yazici MK, Anil Yagcioglu AE, Ertugrul A, Eni N, Karahan S, Karaagaoglu E et al (2011) The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 261:69–78
17. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J (2008) Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry 23:100–108
18. Carra G, Sciarini P, Segagni-Lusignani G, Clerici M, Montomoli C, Kessler RC (2011) Do they actually work across borders? Evaluation of two measures of psychological distress as screening instruments in a non Anglo-Saxon country. Eur Psychiatry 26:122–127
19. Spitzer RL, Williams JB, Gibbon M, First MB (1992) The structured clinical interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 49:624–629
20. Rejas J, Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M (2008) Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 99:23–28
21. Atkins M, Burgess A, Bottomley C, Riccio M (1997) Chlor-promazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull 21:224–226
22. Lehman AF, Steinwachs DM (1998) Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull 24:1–10
23. Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667
24. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jørgensen HA (2009) Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 9:24
25. World Health Organization (WHO) (2011) Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8–11 December 2008. Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/9789241501491_eng.pdf. Accessed 12 Aug 2013
26. Miccoli R, Bianchi C, Odoguardi L, Penno G, Caricato F, Gio-vannitti MG et al (2005) Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 15:250–254
27. Osborn DPJ, Wright CA, Levy G, King MB, Deo R, Nazareth I (2008) Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry 8:84
28. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C et al (2007) Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 49:40–47
29. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al (2007) Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375–2414
30. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359
31. Masulli M, Riccardi G, Galasso R, Vaccaro O (2006) Relationship between smoking habits and the features of the metabolic syndrome in a non-diabetic population. Nutr Metab Cardiovasc Dis 16:364–370
32. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A et al (2009) Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 194:434–438
33. Ripke S, O’Dushlaine C, Chambert K, Moran JL, Ka¨hler AK, Akterin S et al (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45:1150–1159
34. Chen CC, Li TC, Chang PC, Liu CS, Lin WY, Wu MT et al (2008) Association among cigarette smoking, metabolic syndrome, and its individual components: the metabolic syndrome study in Taiwan. Metabolism 57:544–548
35. Parks J, Radke AQ (2008) Obesity reduction and prevention strategies for individuals with serious mental illness. Alexandria: National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council
36. American Diabetes Association (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601
37. Nielsen J, Skadhede S, Correll CU (2010) Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na¨ıve schizophrenia patients. Neuropsychopharmacology 35:1997–2004
38. Foley DL, Morley KI (2011) Systematic review of early cardio-metabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 68:609–616
39. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225–235
40. Carra G, Johnson S (2009) Variations in rates of comorbid substance use in psychosis between geographical areas and mental health settings in the UK. Soc Psychiatry Psychiatr Epidemiol 44:429–447
41. Carra G, Johnson S, Bebbington P, Angermeyer MC, Heider D, Brugha T et al (2012) The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC). Eur Arch Psychiatry Clin Neurosci 262:607–616
42. Bartoli F, Carra G, Crocamo C, Carretta D, Clerici M (2013) Bipolar disorder, schizophrenia and metabolic syndrome. Am J Psychiatry 170:927–928
43. Bartoli F, Carra G, Crocamo C, Carretta D, Clerici M (2013) Metabolic syndrome in people suffering from posttraumatic stress disorder: a systematic review and meta-analysis. Metab Syndr Relat Disord 11:301–308